InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（11 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
11
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the complete record of transactions filed by Iwicki Mark T, Director. Director active across 5 companies, notably Akero Therapeutics, Inc.. Aggregated, 22 filings have been recorded. Split: 0 buy · 11 sells. Total volume traded: €431k. Activity tracked since 28 June 2021. The latest transaction was filed on 12 December 2025 (U). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Iwicki Mark T
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报22 总计
73,576 股@ US$97.0096.5% 占其流量Common SharesSEC:0001193125-25-317936:0
9,398 股Common StockSEC:0001193125-25-312115:0
154,894 股@ US$0.8132.3% 占其流量Common StockSEC:0001415537-25-000004:0
128,631 股Common StockSEC:0001415889-25-021822:0
13,227 股@ US$4.0120.2% 占其流量Common StockSEC:0001415889-25-018317:0
2,450 股0Common StockSEC:0001415889-25-017615:0
9,398 股0Common StockSEC:0000950170-25-082309:0
10,866 股@ US$3.7419.8% 占其流量Common StockSEC:0001104659-25-056986:0
10,866 股@ US$3.7424.7% 占其流量Common StockSEC:0001415889-25-015677:0
22,100 股0Common StockSEC:0001415889-25-001060:0
15,168 股@ US$4.7561.9% 占其流量Common StockSEC:0001415889-24-018374:0
7,392 股@ US$6.0938.1% 占其流量Common StockSEC:0001415889-24-015222:0
14,300 股0Common StockSEC:0001415889-24-000769:0
158,873 股0Common StockSEC:0001415889-23-010281:0
71,715 股Common StockSEC:0001415889-23-009133:0
36,944 股@ US$6.57100.0% 占其流量Common SharesSEC:0001209191-23-024393:0
41,700 股0Common StockSEC:0001415889-23-000636:0
561 股@ US$6.521.9% 占其流量Common StockSEC:0001415889-22-010878:0
7,975 股@ US$0.370.018% mcap1.5% 占其流量Common StockSEC:0001415889-22-007059:0
9,518 股@ US$1.300.071% mcap6.0% 占其流量Common StockSEC:0001415889-22-000402:0
27,598 股@ US$1.800.28% mcap23.3% 占其流量Common StockSEC:0001415889-21-005009:0
7,586 股@ US$5.7737.9% 占其流量Common StockSEC:0001415889-21-003256:0
22 条申报中的 22 条
About Iwicki Mark T
Iwicki Mark T is a Director at KALA BIO, Inc., Merus N.V., Akero Therapeutics, Inc. and Third Harmonic Bio, Inc., and Chief Executive Officer at Kala Pharmaceuticals, Inc. Across the 22 filings, the recent sampled filings show sales of EUR 430952 between 2021-06-29 and 2025-12-12, with the modal transaction nature indicated as Cession.
